Aleph Farms has received permission to market its thin-cut cultivated beef steaks in Singapore, AgFunderNews reported. Chief executive Didier Toubia told the publication that the company is targeting the first half of 2027 for its debut.
Toubia told AgFunderNews that sales will start through selected restaurants after manufacturing partner Cell Agritech begins making commercial batches locally. Singapore will supply the initial output, while Cell Agritech’s Penang site could add volume as demand increases, according to Toubia. He said production transfers are underway there and at The Cultured Hub in Switzerland, with both lines expected to operate during 2027.
Aleph Farms has also simplified its production method, according to Toubia. Cells now partially develop into muscle and fat within the first bioreactor before being combined with a plant-protein matrix, removing a separate cultivation stage. Chief technology officer Neta Lavon told AgFunderNews that the company’s techno-economic analysis used 5,000-liter mammalian-cell bioreactors. That analysis projected a 47% gross margin at conventional-beef price parity, production costs of $6.45 per pound and capital repayment within 2.5 years, according to figures cited by Toubia.
Several commercial details remain unsettled. Toubia said Aleph Farms is discussing plans with Singapore foodservice businesses but cannot yet identify them. Although the company has held Israeli sales clearance since 2023, Toubia told AgFunderNews that Singapore and Switzerland are being prioritized while partner capacity and approvals are developed. He also argued that clearer, faster regulatory routes are still needed to bring validated cultivated meat products to market.
CONCLUSION Aleph Farms is making third-party manufacturing central to its scaling strategy instead of operating its own plants. The commercial test will be whether that model can connect authorized products with functioning capacity and restaurant demand.